DUBLIN, Dec. 18,
2023 /PRNewswire/ -- Theravance Biopharma,
Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH)
today announced that members of its management team including Rick
E Winningham, CEO, and Aziz Sawaf,
CFO, will hold investor meetings during the 42nd Annual
J.P. Morgan Healthcare Conference, January
8-11, 2024, in San Francisco,
CA.
To request a one-on-one meeting with the Theravance Biopharma
management team, please contact us at
investor.relations@theravance.com.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to
deliver Medicines that Make a
Difference® in people's lives. In pursuit of
its purpose, Theravance Biopharma leverages decades of
expertise, which has led to the development of FDA-approved
YUPELRI® (revefenacin) inhalation solution
indicated for the maintenance treatment of patients with chronic
obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage
investigational norepinephrine reuptake inhibitor in development
for symptomatic neurogenic orthostatic hypotension, has the
potential to be a first in class therapy effective in treating a
constellation of cardinal symptoms in multiple symptom atrophy
patients. The Company is committed to creating/driving shareholder
value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and
the Cross/Star logo are registered trademarks of
the Theravance Biopharma group of companies (in
the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan
Specialty L.P., a Viatris company. Trademarks, trade names or
service marks of other companies appearing on this press release
are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-conduct-investor-meetings-during-the-jp-morgan-42nd-annual-healthcare-conference-302017596.html
SOURCE Theravance Biopharma, Inc.